The earnings call highlighted significant regulatory and clinical advancements, particularly with AMT-130 and AMT-260, and a strong financial position. However, these positives were tempered by a notable decline in revenue and increased R&D expenses.

Company Guidance

During the second quarter of 2025 earnings call, uniQure provided detailed guidance on their ongoing clinical advancements and regulatory progress, with a particular focus on AMT-130, a potential first disease-modifying therapy for Huntington's disease. Key metrics shared included the breakthrough therapy designation granted by the FDA in April, alignment with the FDA on the statistical analysis plan and CMC requirements, and the planned BLA submission in Q1 2026. The primary efficacy analysis will use a 3-year change in cUHDRS comparing high-dose patients to a propensity score matched external control. The company also reported an ongoing PPQ campaign and commercial launch preparations for 2026. Revenue for Q2 2025 was $5.3 million, a decrease from $11.1 million in the same period in 2024, with research and development expenses at $35.4 million. Cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, positioning the company well for its planned commercialization efforts.

Regulatory Progress for AMT-130

AMT-130 received breakthrough therapy designation from the FDA and achieved alignment on statistical analysis and CMC requirements for a BLA submission in early 2026.

Significant Clinical Advances

The company reported a 92% reduction in seizure frequency with AMT-260 for epilepsy and is on track for pivotal data releases for both AMT-130 and AMT-191 in Fabry disease.

Strong Financial Position

uniQure's cash, cash equivalents, and investment securities totaled $377 million as of June 30, 2025, providing funding into the second half of 2027.

uniQure (QURE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QURE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.93 / -	-0.91	―	―	―
Jul 29, 2025	2025 (Q2)	-0.90 / -0.69	-1.16	40.52% (+0.47)	―
May 09, 2025	2025 (Q1)	-1.00 / -0.82	-1.36	39.71% (+0.54)	―
Feb 27, 2025	2024 (Q4)	-0.65 / -1.49	-1.52	1.97% (+0.03)	―	―
Nov 05, 2024	2024 (Q3)	-0.99 / -0.91	-1.88	51.60% (+0.97)	―	―
Aug 01, 2024	2024 (Q2)	-1.25 / -1.16	-1.44	19.44% (+0.28)	―	―
May 07, 2024	2024 (Q1)	-1.28 / -1.36	-1.63	16.56% (+0.27)	―	―
Feb 26, 2024	2023 (Q4)	-1.46 / -1.52	0.15	-1113.33% (-1.67)	―	―
Nov 07, 2023	2023 (Q3)	-0.85 / -1.88	-1.02	-84.31% (-0.86)	―	―
Aug 01, 2023	2023 (Q2)	2.36 / -1.44	-0.84	-71.43% (-0.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QURE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$14.98	$13.68	-8.68%
May 09, 2025	$12.25	$12.79	+4.41%
Feb 27, 2025	$11.67	$12.07	+3.43%
Nov 05, 2024	$5.56	$6.06	+8.99%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does uniQure N.V. (QURE) report earnings?

uniQure N.V. (QURE) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is uniQure N.V. (QURE) earnings time?

uniQure N.V. (QURE) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is QURE EPS forecast?

QURE EPS forecast for the fiscal quarter 2025 (Q3) is -0.93.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing